Skip to main content
Book Chapter

Resistance to HER2-Targeted Therapy

  • Theile D
  • Lenz G
  • Momand J
  • et al.
DOI: 10.1007/978-3-319-70142-4_2
N/ACitations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

S2 TL;DR: Given its elevated expression and oncogenic activity, its preferred status as a HER-family signaling partner, and the enhanced activity of HER2-containing heterodimers, HER2 is a valuable pharmacological target for the treatment of Her2+ breast cancer.

Cite

CITATION STYLE

APA

Theile, D., Lenz, G., Momand, J. A., & Kane, S. E. (2017). Resistance to HER2-Targeted Therapy (pp. 35–88). https://doi.org/10.1007/978-3-319-70142-4_2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free